Neoplastic Process – Page 9

OSE Immunotherapeutics Reports 65% Overall Survival Rate in Phase 2 Cancer Vaccine Trial at ASCO 2025

3 months ago talkbio0Tagged ASCO, neo-epitope cancer vaccine, OSE Immunotherapeutics, Pancreatic carcinoma, Phase 2, survival rate, Tedopi

OSE Immunotherapeutics; Tedopi; ASCO 2025; pancreatic cancer; neo-epitope cancer vaccine; phase 2; overall survival rate

Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag’s Adjuvant Melanoma Setback at ASCO 2025

3 months ago talkbio0Tagged Adjuvant Melanoma, ASCO, Clinical Trials, lymphocyte-activation gene 3 protein, human, Malignant neoplasm of lung, Myers, Opdivo, Opdualag, relatlimab, squibb

Opdualag; Bristol Myers Squibb; LAG-3; lung cancer; adjuvant melanoma; ASCO 2025; Opdivo; relatlimab; clinical trial

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

3 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327, Immunotherapy for cancer, milestone payments, Myers, Partnership, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; solid tumors; PD-L1; VEGF-A; cancer immunotherapy; partnership; milestone payments

ASCO 2025: Amgen’s Imdelltra Cuts Small Cell Lung Cancer Death Risk by 40% Versus Chemo

3 months ago talkbio0Tagged 2025, amgen, ASCO, death risk reduction, Imdelltra, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Small cell carcinoma of lung, tarlatamab-dlle

ASCO 2025; Amgen; Imdelltra; tarlatamab-dlle; lung cancer; small cell lung cancer; death risk reduction; overall survival; Phase 3 trial

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion, Expanding Immunology Focus

3 months ago talkbio0Tagged Acquisition, Ayvakit, Biopharma, Blueprint Medicines, elenestinib, Immunology, Infrequent, Mastocytosis, Systemic, pipeline, sanofi

Sanofi; Blueprint Medicines; acquisition; immunology; systemic mastocytosis; Ayvakit; elenestinib; rare diseases; biopharma; pipeline

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

3 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, biotech partnerships, BNT327, immuno-oncology, Malignant Neoplasms, Myers, PD-L1, Solid Neoplasm, squibb, Vascular Endothelial Growth Factor A

Bristol Myers Squibb; BioNTech; BNT327; bispecific antibody; immuno-oncology; cancer; PD-L1; VEGF-A; solid tumors; biotech partnerships

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

3 months ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

Bicara’s Ficerafusp Alfa Shows 46% 2-Year Survival Rate for Head and Neck Cancer Subset at ASCO 2025

3 months ago talkbio0Tagged 2025, Alfa, Antibody Therapy, ASCO, Bicara Therapeutics, Cancer of Neck, Head, Keytruda, Overall Survival, PD-L1, tumor shrinkage

ASCO 2025; Bicara Therapeutics; ficerafusp alfa; head and neck cancer; PD-L1; overall survival; antibody therapy; Keytruda; tumor shrinkage

AstraZeneca Details Its Oral SERD ‘Switching’ Regimen Amid Feasibility Questions

3 months ago talkbio0Tagged AstraZeneca, camizestrant, CDK4/6 inhibitor, Disease Progression, ESR1 gene, Malignant neoplasm of breast, Mutation, Oral SERD, SERENA-6 trial, treatment resistance

AstraZeneca; oral SERD; camizestrant; breast cancer; ESR1 mutation; SERENA-6 trial; CDK4/6 inhibitor; disease progression; ASCO 2025; treatment resistance

Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences

3 months ago talkbio0Tagged Antibody-Drug Conjugates, Astellas, Evopoint Biosciences, Licensing Deal, Neoplasms, therapeutic autologous dendritic cells

Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011